Krsnaa Diagnostics announces strategic collaboration with global radiology AI innovator; shares open in red

Shares of one of the leading diagnostic laboratory chains, Krsnaa Diagnostics, opened on a flat note on Thursday after the company announced a strategic collaboration with a global radiology AI innovator. The shares opened in red, down 1% amid a broader sell-off in the markets. The shares have remained in a lacklustre state in 2026, amid broader pessimism in the markets.

Here is what the exchange filing said

Krsnaa Diagnostics reported that the company has entered into a strategic collaboration with a global radiology AI innovator, AZmed. The exchange filing read, “Krsnaa Diagnostics Limited, one of India’s leading diagnostic service providers, today announced a collaboration with AZmed, a globally recognised medical imaging company specialising in artificial intelligence (AI) solutions for radiology. The collaboration will evaluate AZmed’s AZtrauma solution, part of its Rayvolve AI suite, for the detection and triage of fractures, joint effusions, and dislocations on X-rays”

Krsnaa Diagnostics provides diagnostics, pathology, and teleradiology services in 19 states and union territories through a public-private partnership model. With its vast network of 190+ CT scan centres, 2700+ X-ray centres, and 212 pathology laboratories, the company aims to leverage AZmed’s AI suite for better operational efficiency and drive growth.

AZmed’s Rayvolve solution became the first AI software to receive CE marking for fraction detection in X-rays in 2019. The company has to date processed 15 million images globally, underscoring its scale and importance.

Management outlook

Commenting on the collaboration, Mr. Yash Mutha, Managing Director, Krsnaa Diagnostics Ltd said, “Healthcare AI presents a significant opportunity to transform the future of diagnostic services. By integrating advanced AI technologies into our high-volume radiology operations, we aim to unlock operating leverage, enhance productivity, expand reporting capacity, and build a more scalable operating model enabling Krsnaa to serve more patients with best-in-class technology at highly affordable prices”

Krsnaa Diagnostics share price performance

In 2026, shares of Krsnaa Diagnostics have delivered subdued performance at -31% on a YTD basis. For the trailing twelve months, the shares delivered -37% returns. In the short term, the shares have plunged 8.6% on a monthly basis.